BBIO vs. ANAB
BBIO (BridgeBio Pharma, Inc.) and ANAB (AnaptysBio, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, BBIO returned 0.88%/yr vs 28.21%/yr for ANAB. At a 0.33 correlation, their price movements are largely independent.
Performance
BBIO vs. ANAB - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BBIO achieves a -12.67% return, which is significantly lower than ANAB's 73.48% return.
BBIO
- 1D
- -1.11%
- 1M
- -2.64%
- YTD
- -12.67%
- 6M
- -11.11%
- 1Y
- 68.47%
- 3Y*
- 58.58%
- 5Y*
- 0.88%
- 10Y*
- —
ANAB
- 1D
- 3.37%
- 1M
- -10.55%
- YTD
- 73.48%
- 6M
- 87.15%
- 1Y
- 259.27%
- 3Y*
- 64.14%
- 5Y*
- 28.21%
- 10Y*
- —
BBIO vs. ANAB - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
BBIO BridgeBio Pharma, Inc. | -12.67% | 178.75% | -32.03% | 429.79% | -54.32% | -76.54% | 102.88% | 14.51% |
ANAB AnaptysBio, Inc. | 73.48% | 266.16% | -38.19% | -30.88% | -10.82% | 61.63% | 32.31% | -69.77% |
Correlation
The correlation between BBIO and ANAB is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.25 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.30 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.36 |
Correlation (All Time) Calculated using the full available price history since Jun 27, 2019 | 0.33 |
The correlation between BBIO and ANAB shifts across timeframes, from 0.25 (1 year) to 0.36 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
BBIO:
$13.01B
ANAB:
$1.61B
BBIO:
-$3.76
ANAB:
-$0.91
BBIO:
22.81
ANAB:
7.11
BBIO:
$566.04M
ANAB:
$232.39M
BBIO:
$538.20M
ANAB:
$245.59M
BBIO:
-$602.24M
ANAB:
$52.72M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BBIO vs. ANAB — Risk / Return Rank
BBIO
ANAB
BBIO vs. ANAB - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for BridgeBio Pharma, Inc. (BBIO) and AnaptysBio, Inc. (ANAB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BBIO | ANAB | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.32 | ||
| Sortino ratioReturn per unit of downside risk | -1.82 | ||
| Omega ratioGain probability vs. loss probability | 1.29 | 1.53 | -0.25 |
| Calmar ratioReturn relative to maximum drawdown | 3.40 | 9.28 | -5.88 |
| Martin ratioReturn relative to average drawdown | 8.27 | 22.38 | -14.11 |
Loading charts...
Drawdowns
BBIO vs. ANAB - Drawdown Comparison
The maximum BBIO drawdown since its inception was -92.80%, roughly equal to the maximum ANAB drawdown of -92.08%. Use the drawdown chart below to compare losses from any high point for BBIO and ANAB.
Loading charts...
Drawdown Indicators
| BBIO | ANAB | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.80% | -92.08% | -0.72% |
Max Drawdown (1Y)Largest decline over 1 year | -20.25% | -28.15% | +7.90% |
Max Drawdown (3Y)Largest decline over 3 years | -49.08% | -69.32% | +20.24% |
Max Drawdown (5Y)Largest decline over 5 years | -91.89% | -69.32% | -22.57% |
Current DrawdownCurrent decline from peak | -16.41% | -34.57% | +18.16% |
Average DrawdownAverage peak-to-trough decline | -45.77% | -64.64% | +18.87% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.31% | 11.64% | -3.33% |
Volatility
BBIO vs. ANAB - Volatility Comparison
The current volatility for BridgeBio Pharma, Inc. (BBIO) is 10.47%, while AnaptysBio, Inc. (ANAB) has a volatility of 12.40%. This indicates that BBIO experiences smaller price fluctuations and is considered to be less risky than ANAB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BBIO | ANAB | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.47% | 12.40% | -1.93% |
Volatility (6M)Calculated over the trailing 6-month period | 34.18% | 46.31% | -12.13% |
Volatility (1Y)Calculated over the trailing 1-year period | 46.52% | 68.78% | -22.26% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 85.91% | 65.31% | +20.60% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 83.77% | 75.44% | +8.33% |
Dividends
BBIO vs. ANAB - Dividend Comparison
Neither BBIO nor ANAB has paid dividends to shareholders.
Financials
BBIO vs. ANAB - Financials Comparison
This section allows you to compare key financial metrics between BridgeBio Pharma, Inc. and AnaptysBio, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
BBIO and ANAB have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ANAB has higher volatility (12.40%) compared to BBIO (10.47%). In terms of maximum drawdown, BBIO dropped -92.80% vs ANAB's -92.08%.
ANAB currently has the higher Sharpe Ratio (3.80 vs 1.48), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BBIO and ANAB
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer